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Abstract
Background: Francisella tularensis is an intercellular bacterium often causing fatal disease when inhaled. Previous reports
have underlined the role of cell-mediated immunity and IFNc in the host response to Francisella tularensis infection.
Methodology/Principal Findings: Here we provide evidence for the involvement of IL-17A in host defense to inhalational
tularemia, using a mouse model of intranasal infection with the Live Vaccine Strain (LVS). We demonstrate the kinetics of IL-
17A production in lavage fluids of infected lungs and identify the IL-17A-producing lymphocytes as pulmonary cd and Th17
cells. The peak of IL-17A production appears early during sub-lethal infection, it precedes the peak of immune activation
and the nadir of the disease, and then subsides subsequently. Exogenous airway administration of IL-17A or of IL-23 had a
limited yet consistent effect of delaying the onset of death from a lethal dose of LVS, implying that IL-17A may be involved
in restraining the infection. The protective role for IL-17A was directly demonstrated by in vivo neutralization of IL-17A.
Administration of anti IL-17A antibodies concomitantly to a sub-lethal airway infection with 0.16LD50 resulted in a fatal
disease.
Conclusion: In summary, these data characterize the involvement and underline the protective key role of the IL-17A axis in
the lungs from inhalational tularemia.
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Introduction
Francisella tularensis (Ft), the causative agent of tularemia, is a
small gram-negative facultative intracellular bacterium, which can
infect a broad spectrum of hosts. Infection of humans can be
established by a variety of exposure routes, including infection via
wounds, insect bites, ingestion, or inhalation [reviewed in 1–2].
The infectious dose required to cause human infection varies with
the Francisella strain and route of entry [3]. Ft subspecies tularensis
(type A subspecies) is a highly infectious and virulent pathogen that
can cause a fulminant and often fatal disease by inhalational
exposure to as few as 10 microorganisms. Therefore, type A Ft has
been classified by the Center for Disease Control and Prevention
(CDC) as a Category A bioterrorism agent [4–5].
Despite the disease severity and potential implications of
inhalational tularemia, relatively little is known about the biology
and interrelations of Ft with the host lung. Ft Live Vaccine Strain
(LVS), an attenuated type B strain of Ft, causes a severe respiratory
illness in mice that is commonly used to study inhalational
tularemia [6]. Previous reports have shown that inhaled LVS
infects preferentially airway macrophages and dendritic cells, as
early as 1 h after infection, and continues to replicate within them
[7–8]. Further, we have recently shown that dendritic cell
trafficking is exploited by the bacterium for dissemination from
the lungs to the draining lymph nodes [9]. Later in the course of
infection, bacteria may also be found in considerable amounts in
neutrophils [8].
As Ft is an intracellular pathogen and resides within cells of the
respiratory tract, a role for pulmonary lymphocyte-mediated
immune response is implicated. Lung-residing natural killer (NK)
cells have been shown to become activated and to secrete IFNc
following intransal infection with LVS. Moreover, in vivo NK cell
depletion studies have implied a protective role of NK cells [10].
However, the contribution of NK cells to protection from Ft
remains unsolved as other reports suggested that NK cells may not
exert an essential protective role [11–12]. A protective role for
adaptive T cell mediated immunity against LVS infection was
demonstrated in genetically immunodeficient mice, which died of
overt infection one month after intradermal innoculation [13].
Mice depleted of CD4
+ or CD8
+ T cells, but not of both, [14–16],
or mice with the corresponding knockout mutations [17], survived
primary sublethal intradermal LVS infection, indicating that each
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11176of these subpopulations is capable of clearing primary infection
with the pathogen. With regard to primary pulmonary infection,
CD8
+ T cell deficient mice were similarly susceptible to high dose
intranasal LVS infection as wild type animals [11].
The in vivo contribution of IFNc to the protection from LVS was
clearly demonstrated in gamma interferon knockout (GKO) mice,
which were highly susceptible to LVS infection via all routes
[13,18]. Additional experiments showed that IFNc is required for
early protection. It was reported that the presence of IFNc during
the first 2 days after sublethal intradermal infection ensures
survival [19]. Neutralization of IFNc by antibodies concomitantly
to intradermal sublethal infection resulted in death of the mice
(wild type, nude or SCID strains) within a week [13,19–20]. These
results concurred with earlier studies showing that IFNc
contributes to control of intracellular growth of Ft in macrophages
[21]. Noteworthy, IFNc has an important role in host protection
from a diversity of intracellular bacteria, including L. monocy-
togenes, M. tuberculosis, M. avium, S. typhimurium and C. trachomatis
[reviewed in 22].
Nevertheless, it was previously reported that LVS-infected IL-
12p35
2/2 mice, which fail to mount a robust IFNc response, were
still able to clear intradermal LVS infection [23]. Further, recent
data show that in vivo primed T cells derived from LVS-infected
lungs control intramacrophage LVS growth in vitro, mainly
through IFNc-independent mechanisms [24]. While it was shown
that TNFa contributes to immune response against LVS as well
[20,25], additional T cell derived effectors, such as the IL-17A,
may be involved in the response to LVS.
IL-17A is an early cytokine with pleiotropic effects, involved
mainly in triggering inflammatory responses, such as inflammatory
cytokines (e.g. IL-6, TNFa), chemokines and cell adhesion
molecules, which collectively induce inflammation and neutrophil
recruitment [reviewed in 26]. As a consequence, IL-17A is
involved in host protection against a broad spectrum of pathogens,
including intracellular bacteria [reviewed in 26–28]. The major
lymphocyte sources for IL-17A are the unique Th17 cells, which
are developed due to the function of the IL-23 cytokine, as well as
the cd T cells [reviewed in 29]. Both IL-17A-producing T cell
subpopulations have been implicated in host resistance to various
intracellular bacteria [27–29]. However, the involvement of the
IL-17A axis in inhalational Ft infection has been limitedly studied
so far. Main evidence includes demonstration of the presence of
Th17 cells in lungs of mice intranasally infected with LVS [30],
and that in vitro exposure of human peripheral blood monocytes to
F. novicida induce the production of IL-23 [31].
Here we provide direct and substantial evidence for the
involvement of IL-17A in host defense to inhalational LVS
infection. We identified the IL-17A-producing pulmonary lym-
phocytes and demonstrated the kinetics of their appearance, as
well as of the IL-17A cytokine, in the lungs lavage fluids in
response to inhalational infection. The protective role in vivo of IL-
17A is demonstrated by in vivo neutralization and exogenous
airway administration of cytokines. These results underline the
effect of IL-17A on overall host response and survival from
inhalational LVS infection.
Results
Pulmonary lymphocytes are activated following lethal
intranasal infection with 1006LD50 LVS
To evaluate the effects of inhalational tulatermia on the function
of pulmonary lymphocytes, we have used a model of lethal
intranasal infection of mice by LVS [9]. C57BL/6 mice were
infected with 10
5 CFU of LVS, the equivalent of 1006LD50,
which results in the death of all mice by day 5–6 post infection
(Figure 1A). Live bacteria can be detected in the mediastinal
lymph node (MdLN) already by 4 h, with a dramatic 1000-fold
increase during the first two days [9]. In the lungs, a dramatic
bacterial multiplication was similarly observed (Figure 1B). As
demonstrated previously [9,32], over the last two days, bacterial
numbers in the lung were further increased by additional 10-fold,
while remained constant in the MdLN (Figure 1B).
Lymphocytes involved in cell-mediated immunity, chiefly NK
cells and T cells, were analyzed concomitantly using multi-colored
staining in flow cytometry. NK cells were defined as CD3-
negative/NK1.1-positive cells. T cells were defined as CD3-
positive/NK1.1-negative cells. NK-T cells (CD3-positive/NK1.1-
positive cells) were identified in small fractions and were excluded
(data not shown). No significant alterations in the total NK cell
counts were observed in either lungs or MdLN along the course of
infection (Figure 1C, inset). However, a rapid upregulation of the
activation marker CD69 was observed on the NK cells in the
MdLN already after one day, and in the lungs starting from day 2.
By days 3–4, the vast majority of NK cells in the lung and MdLN
displayed an activated phenotype (Figure 1C), even though the
total NK cell count remained unchanged.
As in the case of NK cells, total T cell count in MdLN and lungs
was essentially not effected by LVS infection (Figure 1D, inset). A
substantial increase in the percentage of activated T cells was
observed, which lagged after NK cell activation by at least one day
in both lungs and MdLN (Figure 1D). This concurs with the innate
properties of NK cells. By day 4, around 60% of the T cells were
activated.
Multi colored analysis with antibodies directed against CD3,
NK1.1, abTCR and CD69 yielded similar results (Supplementary
Figure S1). Analysis of the late activation marker CD25 yielded
similar patterns, but expectedly to a lesser extent (data not shown).
Similar results were observed in another mouse strain, Balb/c
(data not shown). In addition, it should be noted that lymphocytes
were activated only by the presence of live bacteria. This was
demonstrated by instillation of inactivated LVS in a dose-
equivalent to 10
8 CFU. This high dose, which is equivalent to
the dose present in the lung at the peak of infection with 10
5 CFU
live bacteria (see Figure 1B), failed to induce CD69 expression on
NK or T cells, in either the lungs or MdLN (Figure 1E).
Taken together, these results indicate that intranasal LVS
infection triggers a rather rapid activation of lymphocytes involved
in cell-mediated immunity. The increase in activation level
coincides with increase of bacterial load in the infected organ
and reaches maximal levels shortly before mice succumb to
infection. This suggests that the host responds appropriately to the
airway infection by local lymphocyte activation, but the limited
activation kinetics fails to control the fatal outcomes of an
infection, characterized by a high bacterial burden.
The effect of sub-lethal intranasal infection with
0.16LD50 LVS on activation and recruitment kinetics of
pulmonary lymphocytes
In an attempt to search for a possible interrelationship between
lymphocyte function and recovery from infection, we have
examined a model using a lower bacterial infection burden.
Infection with 0.16LD50 of LVS caused a pronounced yet non-
fatal illness in almost all mice, and could be characterized by
several consecutive phases: a subclinical phase (first 2–3 days post
infection), an initial illness evident by a mild decrease in total
weight (days 4–5), a full blown disease evident by pronounced
weight decrease and lethargy (days 6–10), which is followed by a
convalescence phase (day 11, and on) (Figure 2A). These disease
IL-17A in Lung LVS Infection
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contrast to the rapid and consistent decrease in body weight of
mice infected with lethal dose of 1006LD50 (Figure 2A).
Bacterial dissemination and lymphocyte activation were con-
comitantly analyzed at selected time points. During the subclinical
phase (day 2), bacterial counts increased by 100-fold in the lungs,
and could be just barely detected in the MdLN (Figure 2B).
During the peak of disease (days 6–8), bacterial counts further
increased by additional ,100-fold to a maximum of ,10
6 CFU
and ,10
3 CFU per a pair of lungs and MdLN, respectively
(Figure 2B). It should be noted that the systemic bacterial
distribution, as evident by bacterial counts in the spleen, was also
maximal by day 6, but began to subside by day 8 and was already
lower by 100-fold by day 13 (Figure 2B, inset).
Transition from one stage of the disease to another coincided
with a notable change in the dynamics of pulmonary T cell
numbers and state of activation. T cell representation was not
effected during the first days of the subclinical disease. Yet, the
development of clinically evident disease coincided with an
increase in T cell numbers and in their activation as manifested
by CD69 display (Figure 2C). The T cell numbers and activation
status reached their peak with the peak of disease and remained
constant during convalescence. In the MdLN, however, the
observed increase in T cell numbers was transient and returned to
baseline during convalescence (Figure 2C, inset).
The dynamics of pulmonary NK representation in (Figure 2D)
differed substantially from that observed for T cells. The number of
NK cells decreased gradually along the course of the sub-lethal
infection (unlike the case in lethal infection), resulting in a 10-fold
decrease by day 13. Notably, multi colored analysis with antibodies
directed against CD3, NK1.1, abTCR and CD69 yielded similar
results (Supplementary Figure S2). One should note that infection
triggers activation of the pulmonary NK cells, but given the
decrease in total NK cell number, the net number of activated NK
cells remains essentially unchanged along the infection process.
Cytokine production kinetics by pulmonary NK and T
cells during LVS infection
The temporal co-incidence between lymphocyte activation and
the leveling-off in the pulmonary bacterial burden (Figure 2) could
suggest that lymphocytes may exert defensive mechanisms
contributing to bacterial clearance and eventually recovery. To
Figure 1. The effect of lethal intranasal infection with 1006LD50 LVS on activation and recruitment kinetics of lymphocytes in the
respiratory system. (A) Survival of 60 C57BL/6 mice in after intranasal infection with 1006LD50 LVS (Accumulation of six independent experiments
with 10 mice in each experiment); (B) Live bacterial counts in lungs (dark bars) and mediastinal lymph nodes (MdLN) (light bars) at the indicated time
points after infection. The average count in three animals is shown in each time point. (C) CD69 expression analysis on gated NK cells (NK1.1
+CD3
2
cells) in the lungs (closed diamonds) and MdLN (open squares) at the indicated time points after infection (D) CD69 expression analysis on gated T
cells (NK1.1
2CD3
+ cells). The respective insets in both (C) and (D) show the total numbers of NK or T cells; Cells were pooled from three animals at
each time point and analyzed; (E) CD69 expression on gated NK and T cells in the lungs or MdLN three days following instillation of PBS (white bars),
1006LD50 live LVS (black bars) or equivalent dose of inactive LVS (gray bars). Cells were analyzed from three pooled animals. Panels B-E depict a
representative experiments out of three independent experiments performed. Each time point included three animals.
doi:10.1371/journal.pone.0011176.g001
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cytokine expression profile by pulmonary lymphocytes of infected
mice was monitored.
T and NK cells were sorted out using flow cytometry from the
lungs of naı ¨ve mice (day 0), or from LVS-infected mice following
infection with 0.16LD50 at days 2, 4, 7 and 12. Total RNA was
extracted from the sorted cells and the expression of different
cytokines was quantified by Real Time PCR. Unexpectedly, an
early and strong, yet transient, induction of expression of the Th2
cytokines IL-4, IL-5 and IL-13 was measured in pulmonary T cells
by day 2, before clinical manifestations became noticeable
(Figure 3). Concurrently, pulmonary NK cells exhibited a gradual
increase in the expression of IL-4 transcripts, but not of IL-5 or IL-
13. As expected, and in line with previous reports [16], the Th1-
biasing cytokine IFNc was clearly induced in pulmonary T cells by
day 4. This was followed by notable decline, yet IFNc expression
remained mildly enhanced up to day 12. Similarly, pulmonary NK
cells exhibited an early induction of IFNc already by day 2, a
robust peak by day 4 and a subsequent downregulation. IL-15 was
induced only in pulmonary T cells.
Most notably, an early and robust induction of IL-17A was
observed in pulmonary T cells, but not in pulmonary NK cells
(Figure 3). IL-17A induction in T cells is characterized by a sharp
peak on day 4 which subsided subsequently. Interestingly, the IL-
17A peak corresponded temporally with the development clinical
symptoms, while its downregulation corresponded with restraining
of the disease and eventual recovery.
Production of IL-17A in the lungs following intranasal
infection with LVS
To monitor the actual levels of cytokine synthesis, the
accumulation of prototype cytokines was measured in bronchoal-
veolar lavage fluids (BALF) of infected mice. Mice were instilled
with four different infective doses ranging from 0.16LD50 (10
2
CFU) to 1006LD50 (10
5 CFU). BALFs were harvested at different
time points and the concentrations of IL-17A and IFNc were
determined by ELISA (Figure 4A). In agreement with previous
reports [10,16], a clear dose-dependent induction of IFNc was
observed (Figure 4A, right). Higher infective doses resulted in an
earlier induction of IFNc, as well as in increased production of
Figure 2. The effect of sub-lethal intranasal infection with 0.16LD50 LVS on activation and recruitment kinetics of lymphocytes in
the respiratory system. (A) The mean weight of 60 animals in several independent experiments following intranasal infection with 0.16LD50 LVS
(black circles) or with 1006LD50 LVS (gray squares) is presented (Accumulation of six independent experiments with 10 mice in each experiment).
Dashed vertical lines mark the time points selected for bacterial immunological analyses; (B) Live bacterial counts in the lungs (dark bars) and
mediastinal lymph nodes (MdLN) (light bars) at the indicated time points after infection. Inset shows the concomitant live bacterial count in the
spleen. The average counts out of three animals is shown in each time point; CD69 expression analysis on (C) gated T cells (NK1.1
2CD3
+ cells) and (D)
gated NK cells (NK1.1
+CD3
2 cells) in the lungs (closed diamonds) and MdLN (open squares) at the indicated time points after infection. The respective
insets show the total numbers of NK or T cells. Cells were analyzed from three pooled animals at each time point. Panels B–D depicts a representative
experiment out of three independent experiments performed. Each time point included three animals.
doi:10.1371/journal.pone.0011176.g002
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expression in pulmonary lymphocytes (Figure 3), entailed
accumulation of IL-17A in the BALF (Figure 4A left) that reached
its peak in days 3–4. In contrast to the accumulation profile of
IFNc, IL-17A production displayed only a partial dose-dependent
induction pattern. Although higher infective doses resulted in an
earlier induction, there were no apparent differences in time of
induction or in strength of induced response between infection
with 106LD50 and 1006LD50 (Figure 4A, left). Moreover, when
enough time was allowed (day 4 of infection) the amounts of IL-
17A in BALFs of mice infected with 100 CFU was found to be
equivalent to that induced by infection with 10
5 CFU.
Sub-lethal infection (0.16LD50) allowed the monitoring of
cytokine accumulation over a prolonged course of time. The
amounts of IFNc in the BALF increased gradually and remained
very high even through the convalescence period (Figure 4A). This
concurs with the observation depicted in Figure 3, showing that
the mRNA for IFNc remained above basal levels in both T and
NK cells, even during the convalescence period. In contrast, IL-
17A production in sub-lethal infection reached a peak on day 4
that rapidly subsided, concurring with the observed transient
mRNA induction (Figure 3). Inactivated LVS in high dose-
equivalents did not induce, within three days, the production in
the lungs of IL-17A, nor of IFNc or other inflammatory cytokines
such as IL-6 or TNFa (Figure 4B). This is in accordance with the
results depicted in Figure 1E, where lymphocyte activation was
shown to depend on the viability of the instilled bacterium.
Similar to IFNc, IL-6 also displayed a dose-dependent induction
pattern, while TNFa was not induced even in very high infective
doses (Figure 4B). It was previously reported that F. tularensis may
actively inhibit the production of TNFa by macrophages and even
compete with LPS [33].
Taken together, these observations provide evidence that IL-
17A is indeed produced in the lungs in response to inhalational
LVS infection, and in accordance with other observations
[30,34–35]. The inflammatory cytokines IFNc and IL-6 are
Figure 3. Cytokine expression profile in purified pulmonary T and NK cells following infection with 0.16LD50. Figure shows the
expression ratio (see below) of cytokines categorized into three groups (indicated on the left) in two main purified pulmonary lymphocyte
subpopulations, NK and T cells, at indicated time points following infection with 0.16LD50. The quantity of cytokine transcripts was determined as
described in Materials and Methods.
doi:10.1371/journal.pone.0011176.g003
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opposed to IFNc and IL-6, the production of IL-17A could not be
further induced by infection doses beyond 106LD50.
Intranasal LVS infection triggers a robust production of
IL-17A by specific pulmonary T cell subpopulations
In order to evaluate in situ stimulation of pulmonary
lymphocytes following intranasal infection, cells were collected at
different time points post infection with 0.16LD50 LVS.
Production of the selected cytokines by different pulmonary T-
cell lymphocyte subpopulations was characterized using intracel-
lular staining (No additional in vitro stimulus was exerted). Three
main pulmonary T cell subpopulations were analyzed: CD8
+,
CD4
+ and cd T cells. CD8
+ T as well as CD4
+ T cells displayed a
strong, time-dependent increase in the fraction of IFNc-producing
cells (Figure 5, A1-A2), while cd T cells failed to express IFNc.
This is consistent with previous reports [16].
As expected, IL-4, IL-5 were not expressed by CD8
+ T cells at
all (Figure 5, A1), but contrary to the expectation (Figure 3), these
cytokines were not expressed by CD4
+ T cells as well (Figure 5,
A2). Thus, the transient infection-induced enhancement in mRNA
of Th2 cytokines that we have observed in the pooled T-cell
population (Figure 3) does not in fact translate into the protein
level. One cannot exclude, however, the possibility of limited
detection of the technique employed in this study.
LVSinfectionresultedinadistinctincreaseinIL-17A
+producing
cells both in CD4
+ T and cd T cell populations. Among CD4
+ T
cells, IL-17A-producing cells reached the peak on day 6 post-
infection (Figure 5, A2). This subpopulation was identified as Th17
cells,asthey werenegativeforIFNc orIL-4(data not shown).These
results concur with previous reports [30,34]. These Th17 cells
appeared on day 5, peaked at day 6 (3.2% of total population, data
not shown) and subsided gradually (Figure 5, A2). Remarkably, a
robust and early induction of IL-17A production by cd T cells was
observed as early as day 2-post infection, and reached the peak by
day 6 (40% of the cd T cells, data not shown) (Figure 5, A3).
The production of IL-17A by both Th17 and cd T cells,
exhibited a dose dependent pattern. Infection with 1006LD50
significantly enhanced IL-17A production as compared to
infection with 0.16LD50, when measured on day 2 (Figure 5,
B2-B3). CD8
+ T cells failed to produce IL-17A even at the high
infection dose (Figure 5, B1). A dose dependent pattern was also
Figure 4. Accumulation of cytokines in the respiratory tracts following intranasal infection with LVS. (A) IL-17A and IFNc concentrations
in BALFs of mice infected with various infective doses at the indicated time points. Each of the concentration values represents the mean of 2–3
BALFs collected from individual animals. The letter ‘‘D’’ indicates that the mice infected with the corresponding infective doses could not be
measured due to death of the animals. (B) The mean concentration of the indicated cytokines three days post instillation of PBS (naı ¨ve), inactive (iLVS)
or live (LVS) bacteria. Each of the concentration values represents the mean of 2–3 individual BALFs. Representative experiment out of three
performed is shown in panels A and B.
doi:10.1371/journal.pone.0011176.g004
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+ T and CD4
+ T cells,
but not by cd T cells (Figure 5, B1-B3).
The contribution of various pulmonary T-cell
subpopulations to production of IL-17A
The expression of IL-17A was analyzed in total lung single cell
suspensions along the course of sub-lethal infection. Lymphocyte
Gate was determined by using physical parameters (forward and
side scatters). The expression of IL-17A was mostly below
detection threshold in the non-lymphocyte cells (determined as
all of the cells that were not included in the Lymphocyte Gate)
throughout the course of infection (Figure 6A). IL-17A was
detected only in some cells within the Lymphocyte Gate, an
expression that increased during the course of infection (Figure 6A).
Figure 5. Expression of cytokines by specific pulmonary T cell subpopulations following intranasal infection. Three T cell
subpopulations (indicated on the left) were examined for expression of selected cytokines. Panel (A1–A3) show the number of positive cells, stained
intracellularly for the production of the indicated cytokines at the indicated time points following infection with 0.16LD50 LVS; (B1–B3) compare the
number of cells expressing IFNc or IL-17A at day 2 post infection with 0.16LD50 (black bars) or with 1006LD50 (gray bars). N/D stands for Not Detected.
Cells were analyzed from three pooled animals at each time point. Figure depicts a representative experiment out of three experiments performed.
doi:10.1371/journal.pone.0011176.g005
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be mostly attributed to lymphocytes.
To evaluate the contribution of the various pulmonary T-cell
populations to the net production of IL-17A, the actual number of
the relevant cells (CD4
+ and cd T cells) was determined in the
course of infection. The basal absolute amount, prior to infection,
of the CD4
+ T cells was found to be .100-fold higher than that of
cd T cells (Figure 6, B–C). Cell number analysis along sub-lethal
infection showed that the amount of pulmonary cd T cells has
peaked dramatically by days 5-6 and subsided subsequently
(Figure 6B). In contrast, CD4
+ T cells exhibited a persistent
gradual increase in absolute numbers, starting from day 6 and on
(Figure 6C). This kinetics underlines the innate-like properties of
cd T cells, as compared to the adaptive-like kinetics of CD4
+ T
cells. Nevertheless, there were still at least 10-fold more CD4
+ T
cells than cd T cells throughout the course of disease (compare
Figure 6B and 6C).
The actual numbers of IL-17A producing cells in these two T
cell populations were extrapolated. Results suggest that CD4
+
cells are the major contributors to IL-17A production in infected
LVS lungs, yet cd T cells may have a role in the initial phase of
infection (Figure 6D). This is underlined when the representation
of each subpopulation within the IL-17A-producing cells is
calculated (Figure 6E). In accordance with the rapid kinetics
of cd T cells, the amount of IL-17A
+cd T cells was comparable
to that of the CD4
+IL-17A
+ cells until Day 5, comprising
25–40% of the total IL-17A
+ cells (Figure 6E). From day 6 and
on the proportion of IL-17A
+ cd T cells has consistently declined
down, as Th17 cells became the dominant source for IL-17A
(Figure 6E).
Figure 6. Kinetics of IL-17A producing pulmonary T cells following intranasal infection. (A) shows the IL-17A staining in total pulmonary
non-lymphocyte cells (left) or lymphocytes (right), at the indicated time points. The total number of pulmonary cd (B) or CD4
+ (C) T cells at indicated
time points post intranasal infection with 0.16LD50 LVS; (D) Total number of IL-17A
+ pulmonary cd or (gray bars) or CD4
+ (black bars) T cells at
indicated time points post intranasal infection. (E) Percentage of IL-17A-positive T cell subset out of the total IL-17A-positive T cells. Cells were
analyzed from three pooled animals at each time point. Figure shows a representative experiment out of three performed.
doi:10.1371/journal.pone.0011176.g006
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and rapid induction in the production of IFNc, which peaked on
day 8 and then declined. IL-4, IL-5 and IL-17A were not
expressed by NK cells at all (data not shown).
cd T cells are not essential for survival from intranasal LVS
infection
Since cd T cells were identified as an early source for IL-17A
during LVS infection (Figure 6), their role in the response to LVS
was tested. TCRd
2/2 (KO) and wild type (WT) C57BL/6 mice
were infected either with a lethal dose of 106LD50 or with a sub-
lethal dose of. Although the mean time to death of TCRd
2/2 mice
infected with 106LD50 was slightly lower than that of the WT
mice (6.37 days vs. 6.72 days), this difference was not statistically
significant (Figure 7A).
Infection with a dose of 0.16LD50, which is sub-lethal to WT
mice, proved to be sub-lethal to the KO mice as well, suggesting
that cd T cells are not essential for mice recovery from infection.
Moreover, following sub-lethal infection, TCRd
2/2 mice dis-
played a similar course of disease to WT mice, except for the
period of convalescence (Figure 7B). Indeed, convalescence period
was significantly prolonged in TCRd
2/2 as compared to WT,
with a lag of at least 7 days in reaching basal body weight
(Figure 7B). These results indicate that cd T cells play only a
partial role in the response to LVS, which is not essential for
survival.
Exogenous administration of IL-17A moderately delays
time of death from lethal intranasal LVS infection
The potential beneficial effect of exogenous administration of
IL-17A was tested in a model of lethal infection with 106LD50.
Systemic administration of 3 mg of IL-17A (intraperitoneal
injection) on the day of infection and on day 3 did not provide
any benefit when compared to the control PBS treatment
(Figure 8A). Similar results were obtained when IL-17A was
administered one day before the infection (data not shown). We
therefore hypothesized that IL-17A should be administered
directly to the target organ of infection, the respiratory tract.
Intranasal instillation of IL-17A resulted in enhanced concentra-
tions of TNFa and IL-6 in the BALF, but not of IFNc, one day
after instillation (Figure 8B). This concurs with known biological
activities of IL-17A [26].
The effect of intranasal instillation of IL-17A (at days 0 and 3)
was tested in escalating doses: 3 mg, 10 mg and 30 mg per mouse,
as compared to instillation of the carrier only (PBS). Instillation of
3 mg did not provide any benefit as compared to control PBS
(Figure 8C). The mean time to death was increased mildly, yet in a
statistically significant manner, by 0.7 days when 10 mg of IL-17A
were administered. This benefit was reproduced in several
independent experiments (Figure 8D). A similar effect was
observed with 30 mg, which was not superior to administration
of 10 mg of IL-17A (Figure 8C). Thus, the mild beneficial effect
cannot be further improved by higher doses of exogenous IL-17A.
Exogenous administration of IL-23 moderately delays
time of death from lethal intranasal LVS infection
The cytokine IL-23 acts upstream to IL-17 in the IL-17 axis,
and it promotes differentiation of Th17 cells and secretion of IL-
17A [26]. We have therefore tested the effect of exogenous
administration of IL-23 in the model of lethal infection with
106LD50. As opposed to IL-17A, even a single systemic
administration of 3 mg of IL-23 (intraperitoneal injection) on the
day of infection provided a moderate, yet statistically significant,
benefit when compared to the control PBS treatment. The mean
time to death was increased by almost 1 day (Figure 9A). A similar
1-day delay in the onset of death was also observed when 3 mgo f
IL-23 were administered intranasally at the day of infection, as
compared to control PBS instillation (Figure 9B). The beneficial
effect of IL-23 could be accounted for by a combined induction of
IL-17A and IFNc, since instillation of IL-23 to naı ¨ve mice induced
the production of both cytokines (Figure 9C). In conclusion,
administration of IL-23 yielded only a partial effect, which was
similar to the effect of exogenous IL-17A.
IL-17A is essential to the response against sub-lethal
intranasal LVS infection
In order to directly test the in vivo role of IL-17A in the response
to sub-lethal LVS infection, IL-17A was depleted in vivo using anti-
Figure 7. The effect of cd T cells knockout on response to intranasal LVS infection. Wild type (WT) or TCRd
2/2 (KO) C57BL/6 mice were
intranasally infected with a lethal 106LD50 (A) or a sub-lethal 0.16LD50 (B) infective dose. (A) compares the mean time to death (MTTD) and (B)
compares the mean percentage of body weight monitoring of the WT and KO groups.
doi:10.1371/journal.pone.0011176.g007
IL-17A in Lung LVS Infection
PLoS ONE | www.plosone.org 9 June 2010 | Volume 5 | Issue 6 | e11176IL17A antibodies. The efficacy of IL-17A depletion was
determined by measuring IL-17A in the BALF of mice 6 days
post intranasal infection with 0.16LD50 and intraperitoneal
administration of the neutralizing antibody, or of PBS as control.
At this time point, the IL-17A concentration in the BALF of PBS-
treated animals was around 50 pg/ml, as compared to below
detection level in the mAb-treated animals (data not shown).
Next, mice were infected with 100 CFU (0.16LD50) and treated
with neutralizing anti IL-17A antibodies or PBS on the day of
infection, and again seven days post-infection. In the PBS-treated
group, all mice except of one successfully recovered from the
disease and survived. Namely, five mice infected with 0.16LD50
LVS treated with rat IgG2a isotype control did not succumb to the
infection and exhibited a morbidity pattern similar to that of the
PBS-treated mice (data not shown). Strikingly, treatment of mice
with the neutralizing anti IL-17A led to a substantially decreased
survival, as 66.6% of the infected mice died of infection, all on day
10 (Figure 10 A1). In terms of morbidity, monitored by body
weight, the surviving mAb-treated mice exhibited a generally
similar pattern of weight loss to that of PBS-treated mice (Figure 10
A2). However, the mAb-treated mice that eventually died on day
10 exhibited an accelerated course of disease.
Similar results were obtained in an experiment where mice were
infected with 30 CFU. In the PBS-treated group, all mice except of
one, successfully recovered and survived. The treatment with anti
IL-17A antibodies ultimately resulted in the death of 70% of the
mice (Figure 10 B1-B2). In this experimental setup, the effect of
IL-17A depletion on morbidity was clearly manifested. Among the
mAb-treated group, the mice that eventually died demonstrated a
sharp drop in body weight evident from day 6 post-infection.
Moreover, the effect of antibody treatment on morbidity could
also be observed in the surviving mice (nadir of 75%), as compared
to the PBS-treated mice (nadir of 82%) (Figure 10 B2).
Treatment of mice with neutralizing anti-IL17 antibodies
accelerated also the course of disease in mice infected with a
lethal dose of 56LD50. The mean time to death of PBS-treated
mice was 9.1 days and of the anti-IL17 treated mice was 7.8 days
(p value ,0.05, data not shown). Treatment with anti IL-17A
Figure 8. The effect of IL-17A administration on response to intranasal LVS infection. WT C57BL/6 mice were infected intranasally with a
lethal dose of 106LD50. (A) shows the effects on mice survival of intraperitoneal systemic administration of IL-17A or carrier only at days 0 and 3 post
infection with 106LD50. The time of death of each animal is shown; (B) depicts the effect of intranasal administration of IL-17A in naı ¨ve mice on
cytokine production. 24 h after instillation of IL-17A (black bars) or PBS carrier (gray bars), BALFs were harvested from three individual animals and the
concentrations of the indicated cytokines were determined. Results show the mean concentration values; (C) shows the effects of intranasal
administration of IL-17A or carrier only at days 0 and 3 post-infection with 106LD50. Three doses of IL-17A were tested, as indicated in the figure. The
time of death of each animal is shown. Asterisks represent a statistically significant difference (P value ,0.05). Results of one experiment out of two
performed is presented; (D) shows the pooled results of three independent experiments performed only with the dose of 10 mg IL-17A versus carrier
only. Each experimental mice group in each independent experiment included five mice.
doi:10.1371/journal.pone.0011176.g008
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a lethal dose of 106LD50. (A) shows the effects on mice survival of systemic intraperitoneal administration of IL-23 or carrier only at the day
of infection with 106LD50. The time of death of each animal is shown; (B) shows the results of intranasal administration of IL-23 or carrier only
at the day of infection with 106LD50. (C) depicts the effects of intranasal administration of IL-23 in naı ¨ve mice. 24 h after instillation of IL-23
(black bars) or PBS carrier (gray bars), BALFs were harvested from three individual animals and the concentrations of selected cytokines were
determined. Results show the mean concentration values; * represents statistical significance of P value ,0.05, ** represents statistical significance
of P value ,0.01. Figure shows the result of a representative experiment out of three performed. In the other experiments, each mice group
included 5-6 mice.
doi:10.1371/journal.pone.0011176.g009
Figure 10. The effect of anti IL-17A antibody administration on response to intranasal LVS infection. (A) WT C57BL/6 mice were
infected with 100 CFU (0.16LD50). Mice were then injected with 100 mg of neutralizing anti IL-17A mAb (n=6 animals) or with carrier only
(n=10 animals) on days 0 and 7 post infection. (A1) depicts the cumulative survival of the two experimental groups, P value ,0.05; (A2) depicts
body weight monitoring of PBS-treated mice (gray diamonds), mAb-treated mice that eventually died (black squares, n=4 animals) or recovered of
the disease (white squares, n=2 animals). Figure shows one experiment out of two performed (with similar results); (B) WT C57BL/6 mice were
infected with 30 CFU. Mice were then injected with 100 mg of neutralizing anti IL-17A mAb (n=10 animals) or with carrier only (n=10 animals) on
days 0 and 7 post infection. (B1) depicts the cumulative survival of the two experimental groups, P value ,0.01; (B2) depicts body weight
monitoring of PBS-treated mice (gray diamonds), mAb-treated mice that eventually died (black squares, n=7 animals) or recovered of the
disease (white squares, n=3 animals). Figure shows one experiment out of two performed (with similar results). *denotes P value ,0.05; ** denotes
P value ,0.01.
doi:10.1371/journal.pone.0011176.g010
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(data not shown).
In conclusion, these results show that IL-17A plays a pivotal role
in the immune response against intranasal LVS infection.
Discussion
One of the most severe forms of tularemia is inhalational tularemia,
which directed the present work towards studying components of
the pulmonary immune system in the response to airway LVS
infection. We have utilized an in vivo murine model of sub-lethal
inhalational LVS infection, which causes a self limiting disease, in
an attempt to identify critical protective determinants, which could
lead to the development of novel preventive and interventional
modalities.
Temporal overlay of bacterial counts and immune activation
following this sub-lethal infection showed that on day 8 bacterial
counts peaked, body weight was at the nadir, and pulmonary
lymphocytes (T & NK cells) reached maximal activation, which
was sustained thereafter (Figure 2). The immune activation plateau
coincided with clearance of the bacteria locally and systemically, as
well as with clinical convalescence (Figure 2). This would suggest
that the cellular immune responses might be involved in mediating
the clearance of LVS and eventual recovery.
The interrelationship of this intracellular bacterium with the
immune system is under continuous investigations and appears to
be complex. It involves recruitment of host anti-bacterial measures
such neutrophils, macrophages, inflammatory response and most
importantly Th1-mediated specific IFNc and CTL responses
[11,16,21,24]. However, several bacterial immune evasion mech-
anisms have already been identified, including downregulation of
CD14 and TLR expression, as well as downregulation of post
receptorial signaling machineries [36]. In addition, Ft was shown
to stimulate the production of suppressive mediators like TGFb
[7,33] or Prostaglandin E2 [37].
Due to the temporal coincidence between pulmonary lympho-
cyte activation in the sub-lethally infected lungs, bacterial clearance
and convalescence (Figure 2), we have screened the kinetics of
mRNA production of an array of cytokines in the isolated
pulmonary lymphocytes during infection. Surprisingly, while the
expected upregulation of Th1 cytokines such as IFNc was observed
[11,16,21,24], it was preceded by a strong and early induction of
Th2 transcripts, such as IL-4, IL-5 and IL-13. In fact, it was
previously reported that Ft-infected macrophages release Prota-
glandinE2thatpromotesTh2-likeresponses[37].Inmostcases,the
effective immune response elicited against intracellular pathogens is
Th1 cell-mediated immunity [38–39]. Indeed, it was previously
reported that humoral antibody-mediated response is probably only
minimally involved in the protection from LVS infection [6]. Thus,
diversion of the elicited immune response by LVS bacteria towards
humoral response could emerge as an immune evasion mechanism.
It should be noted that LVS is a highly attenuated strain and the
possible relevance of such mechanism should be investigated in the
virulent SchuS4 strain. Noteworthy, nevertheless, is the observation
that the early and prominent increase in Th2 transcripts was short-
lived (Figure 3) and did not culminate in production of measurable
cytokines in vivo (Figure 5). The observed termination of the early
expression of Th2 cytokines could occur due to the concurrently
elicited strong Th1 response. For example, early production of IL-
12 by activated macrophages and massive secretion of IFNc by NK
cells could redirect the immune response towards Th1.
While it is well established that IFNc response plays a central role
in anti Ft response, a study on mice deficient of the IL-12p35
subunit suggested that other mechanisms could be involved in host
response to LVS. These mice are unable to form a functional IL-12
complex, which hinders their ability to mount an IFNc response.
Yet, they were still able to be cleared of intradermal LVS infection
[23]. An alternative mechanism that could be involved in protection
from LVS could depend on the IL-17 axis. Notably, IL-12p40,
which is still expressed in IL-12p35
2/2 mice, can associate with the
IL-23p19 subunit to form a functional IL-23 [40]. IL-23 promotes
the IL-17 axis through differentiation of helper T cells into IL-17A-
producing Th17 cells [41]. IL-17A is an early proinflammatory
cytokine, promoting several effective host defensive mechanisms
[reviewed in 26] against a broad spectrum of pathogens, including
major intracellular bacteria such as M. tuberculosis, M. pneumoniae and
L. monocytogenes [reviewed in 26–28], but it has been only poorly
investigated so far in Francisella infections.
Here we show that IL-17A is produced in the lungs in response
to airway LVS infection (Figure 4). This was demonstrated at the
mRNA level, the overall cytokine level and the amount of IL-17A-
producing lymphocytes (cd T cells and Th17 cells) in the infected
lungs (Figures 3–6). Noteworthy, the production of IL-17A
following sub-lethal airway infection was of transient nature,
peaking around days 4-6 and apparently preceding the full-blown
disease (days 6–8). This profile could thus suggest that IL-17A is
involved in restraining the infection and preventing it from
becoming fulminant. However, as opposed to IFNc and IL-6, the
production of IL-17A could not be further induced by infection
doses beyond 106LD50, which could be explained by reaching the
maximal production capacity by the host or, alternatively, by a
bacterial inhibitory mechanism that hinders the production or
affect the sustainability of IL-17A.
cd T and CD4
+ Th17 cells were identified as the main
pulmonary lymphocyte sources for IL-17A following LVS airway
infection (Figures 5–6). It should be noted that the gating approach
was based on forward and side scatters, which is suboptimal (e.g. to
FSC-A vs. FSC-W) when non-lymphocyte populations may be
involved. Important roles in host response to various pathogens
were previously demonstrated for both T cell subpopulations. The
anti pathogen roles of cd T cells, a unique subpopulation of T cells
with invariant T cell receptor and innate-like properties, has
gained much attention lately, especially due to their role in
secretion of IL-17A [29]. It was very recently shown that the IL-
17A-producing cd T, but not other cd T cells, express TLR1,
TLR2 and dectin-1, respond to IL-23 and recognize various
pathogens [42]. The role of cd T cells in tularemia has been poorly
studied so far, including mainly demonstrations of a substantial
increase in the proportion of circulating cd T cells in human
tularemia patients [43–44]. Our results suggest that pulmonary cd
T cells are an early source for IL-17A (Figure 6) and that they
exhibit rapid activation kinetics evident by CD69 expression (data
not shown). Nevertheless, TCRd
2/2 knockout mice were not
more vulnerable airway LVS infection (Figure 7), as they did not
succumb to sub-lethal airway infection and the mean time to death
due to lethal airway infection was not significantly different from
the wild type mice. Noteworthy, it was previously reported that
cdTCR
2 mice do not succumb to sub-lethal intra-dermal LVS
infection as well [17]. Interestingly, the airway infected knockout
mice did exhibit a delayed recovery period from sub-lethal
infection, as compared to the wild type mice. Thus, cd T cells are
not essential for mounting effective protective response to LVS,
but conceivably they play some role in clearance of the pathogen.
Notably, exogenous administration of IL-17A during lethal
airway infection yielded limited results. A mild beneficial effect was
observed only following administration of high doses of recombi-
nant IL-17A and it could not be further enhanced with higher
doses (Figure 8). Exogenous administration of IL-23 yielded
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of exogenous cytokine administration in lethal airway infections
could be explained by: a) failure to reach an adequate functional
concentration in the target organs; b) IL-17A activity and stability
could be altered in the microenvironment of LVS-infected
respiratory tract; c) the existence of a putative counter mechanism
of IL-17A exerted by the bacteria, which overcomes the
administered cytokine; d) the limited ability of the host to
adequately respond to IL-17A and develop a clinically significant
effect may be physiologically limited.
While exogenous administration of IL-17A did not provide fully
satisfying results, we directly show the protective role of IL-17A in
anti-LVS host response by the in vivo IL-17A neutralization
experiments (Figure 10). Indeed, in vivo neutralization of IL-17A
with anti IL-17A monoclonal antibody caused the majority of the
treated mice to develop a more severe disease and succumb to an
otherwise sub-lethal dose (100 CFU or 30 CFU, Figure 10).
Accordingly, the anti IL-17A shortened the time to death in a
lethal infection setup of 56LD50 (data not shown). The depletion
of IL-17A also exacerbated disease manifestations, evident mainly
following infection with 30 CFU (Figure 10). The exact
mechanisms by which the IL-17A response contributes to host
protection against LVS is still unclear, but could be mediated, for
example, by neutrophil recruitment or induction of inflammatory
cytokines such as IL-6, GM-CSF and TNFa [45–46]. The short-
lived IL-17A response probably reflects the tight regulation on this
immune effector arm, which can facilitate severe inflammatory
responses and autoimmune manifestations [26]. Since we
demonstrate that the presence of IL-17A is important for
protection from LVS (Figure 10), but the IL-17A-secreting cd T
cells are non-essential (Figure 7), it could be speculated that other
cellular sources of IL-17A, such as Th17 -cells (Figure 5), produce
sufficient amounts of IL-17A to resolve the low-dose infection.
It wasvery recently publishedthat IL-23-Th17pathway regulates
the IL-12-Th1 cell pathway and is required for protective immunity
against F. tularensis live vaccine strain [34]. Most of the work in that
report was performed with a series of knockout mice, including
knockouts of IL-23, IL-17A and IL-17A-Receptor. In vivo depletion
of IL-17A with an antibody impaired bacterial clearance from the
lungs [34]. In another very recently published report, the protective
role of IL-17A against intradermal LVS infection was demonstrated
with IL-17A knockout mice, while effects of exogenous cytokines
promoting the IL-23/IL-17A axis were demonstrated in vitro in an
intracellular LVS growth system [35].
Here we provide comprehensive accurate data on the kinetics of
the IL-17-mediated response, including the production of IL-17A
in the lungs and the identity of the lymphocyte sources for IL-17A,
with regard to sub-lethal and lethal infective doses. Furthermore,
we show that in vivo modulation of the IL-23/IL-17A axis either by
administration of exogenous cytokines (IL-17A or IL-23) or IL-
17A depleting antibody, does not only result in immune
modulation or altered bacterial clearance, but also directly affect
resilience of animals to intranasal LVS infection, evident by
clinical endpoints such as morbidity patterns (reflected by body
weight) and cumulative survival.
Taken together, the accumulating evidence indicates that the
IL-23/IL-17A axis plays a role in the protection of the infected
host against F. tularensis.
Materials and Methods
Ethics statement
All experiments reported here were conducted in compliance
with the guidelines of the animal use committee at the Israel
Institute for Biological Research and are in accordance with the
Animal Welfare Act.
Antibodies and cytokines
The following fluorochrome-conjugated monoclonal antibodies,
which were all purchased from eBioscience were used in this work
(the number in brackets represents the titrated working concen-
tration): PE-conjugated anti-Thy1.2 (0.05 mg/10
6 cells), PE-
Cy5.5-anti mouse CD3 (0.1 mg/10
6 cells), FITC-anti mouse ab
TCR (0.05 mg/10
6 cells), FITC-anti mouse CD4 (0.1 mg/10
6
cells), APC-anti mouse CD8 (0.05 mg/10
6 cells), APC-anti mouse
NK1.1 (0.15 mg/10
6 cells), FITC-anti mouse DX5 (0.15 mg/10
6
cells), PE-anti mouse CD69 (0.1 mg/10
6 cells), PE-anti mouse
CD25 (0.1 mg/10
6 cells), PE-anti mouse IFNc (0.1 mg/10
6 cells),
PE-Cy5.5 anti mouse IL-4 (0.1 mg/10
6 cells), PE-Cy5.5 anti mouse
IL-5 (0.125 mg/10
6 cells), PE-anti mouse IL-17A (0.125 mg/10
6
cells), APC-anti mouse cd TCR (0.1 mg/10
6 cells). All appropriate
fluorochrome-conjugated isotype controls were purchased from
eBioscience. In addition, the neutralizing anti mouse IL-17A and
the rat IgG2a isotype control were used (R&D System,
Minneapolis MN USA, clone 50104). The anti IL-17A antibodies
(for flow cytometry and for in vivo neutralization) are specific to this
isoform and do not cross react with other isoforms. Recombinant
murine IL-17A was purchased from Prospec (Rehovot, Israel) and
recombinant murine IL-23 was purchased from R&D Systems.
Animal studies
The main mouse strain used in this study was C57BL/6
(Harlan, Israel). Other strains used were the TCRd
2/2 mice
(Jackson laboratories) and their C57BL/6 background (Jackson
laboratories), as well as Balb/c mice (Harlan, Israel). Intranasal
instillation to anesthetized mice was performed in a volume of
25 ml. Anesthesia was performed by intraperitoneal injection of
Ketamine and Xylasine diluted in sterile PBS. In experimental
protocols in which mice were infected and treated at the day of
infection intranasally, both instillations were performed under a
single anesthesia. Mice were first instilled with the treatment and
after several minutes with the bacteria. Systemic administration of
cytokines or antibodies was performed by intraperitoneal injection
of the appropriate constituent diluted in 0.5 ml. Harvesting of
bronchoalveolar lavage fluids (BALF) was performed in deeply
anesthetized mice following previously reported methodology [9].
Briefly, the trachea was surgically exposed and cannulated with a
23g plastic catheter. The inserted catheter was further fixed in
place with a 3-0 silk tie. Using a 1 ml syringe, 1 ml of PBS was
pushed through the catheter and immediately collected back. In
almost all cases, 700 ml of BALF were obtained. In rare cases of
blood contamination, the samples were excluded and discarded.
Tissue processing
Various organs, including spleen, lungs and mediastinal lymph
nodes (MdLN) were harvested from euthanized mice. Organs were
rendered into single cell suspensions by mechanical and/or
enzymatic digestion as previously described [9]. Briefly, spleens
were gently crushed with a 3 ml syringe (BD Biosciences), gently
pipetted and passed through cell strainer (BD Biosciences) to
eliminate aggregates. Lungs were washed from external blood and
minced into 1–2 mm pieces. The minced pieces were further
incubated for 1 h with Liberase Blendzyme 3 (Roche) in a final
concentration of 2 mg/ml at 37 degrees Celsius, followed by 5
minute treatment with 100 U/ml of DNAse I (Roche) in 37
degrees Celsius. Mediastinal lymph nodes were subjected only to
enzymatic digestion, exactly as described above. After the
incubation with the enzymes, suspension was thoroughly pipetted
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then passed through a cell strainer.
Bacterial preparation and enumeration
Francisella tularensis live vaccine strain (ATCC 29684) stocks were
plated on CHA agar (GC Medium base, Difco, supplemented with
1% hemoglobin and 1% Iso-Vitalex BD, France). Working stocks
were prepared from single individual colonies exhibiting the large-
light phenotype [47]. For cell and animal infection experiments,
bacteria were grown at 37 degrees Celsius to mid log phase (optical
density of 0.1–0.2 at 660 nm) in TSBC (TSB Difco, supplemented
with 0.1% cysteine) in a gyrostatory shaker. Bacteria were washed
and then re-suspended at the desired concentration in PBS for
animal infection experiments. The intranasal LD50 of our LVS
bacterial stocks was rigorously determined and defined as 10
3
CFU for the C57BL/6 mice [9], which was similar to reports by
others [32]. Bacterial enumeration in various organs was
performed by serial dilutions of single cell suspensions, plating
on CHA for 48–72 hours in 37 degrees Celsius and counting of
formed colonies. Killed bacterial suspensions were generated by
incubating log phase bacterial cultures in the presence of 0.4%
formaldehyde overnight at room temperature, followed by
extensive washing with PBS.
Flow cytometry
Single cell suspensions derived from spleen, lungs or MdLN
were centrifuged at 500g for 5 minutes. Red blood cells were lyzed
using Red Cell Lysis solution (Sigma-Aldrich, Israel) according to
manufacturer’s instructions and washed with FACS buffer (PBS/
BSA 0.5%/Sodium-Azide 0.02%). Fc receptors were blocked by
incubation of 1610
6 cells with 1% Fc Block (Miltenyi, Germany)
diluted in 50 ml FACS buffer, for 15 minutes on ice. Cells were
then plated in 96-U microplates (Nunc). The appropriate antibody
mixes or single stains in the optimized concentrations (diluted in
FACS buffer) were then added onto the Fc blocked cells in
additional 50 ml and incubated for 30 minutes on ice in dark
conditions. The plate was then centrifuged at 500 g for 5 minutes
in 4 degrees Celsius, supernatant was removed and each well was
further washed by 200 ml of FACS buffer. After the wash, cells
were transferred to FACS acquisition tubes through a mesh to
eliminate aggregates for analysis in FACScalibur instrument and
CellQuest software. The lymphocyte subpopulation was gated
according to standard Forward and Side Scatter parameters, in
order to avoid irrelevant larger cell populations or smaller cell
populations, fragments and debris. A low proportion of dead cells
(,10%) was verified by PI staining. When possible, PI was used in
the same test tube with the antibodies, depending on the
fluorescence channels occupied by the antibodies.
Intracellular cytokine staining
This approach is based on the assumption that the pulmonary
lymphocytes isolated from infected lungs were already stimulated
in vivo. The isolated pulmonary lymphocytes cells were pre-
incubated in 37 degrees Celsius for 4 hours with Brefeldin A
(eBioscience) diluted in complete medium, comprised of RPMI-
1640 (Biological Industries, Bet Haemek, Israel) supplemented
with 10% heat inactivated fetal calf serum (Biological Industries,
Bet Haemek, Israel) and 1 mM of Pen-Strep (Biological Industries,
Bet Haemek, Israel), non essential amino acids (Biological
Industries, Bet Haemek, Israel), L-glutamine (Biological Industries,
Bet Haemek, Israel) and sodium pyruvate (Biological Industries,
Bet Haemek, Israel). The cells were not incubated with any
exogenous stimulant. Pen-Strep was added to eliminate residual
bacteria that were carried over from the in vivo infection. Next the
cells were collected, centrifuged and washed with FACS buffer.
After the cells were stained extracellularly as described above, cells
were fixed and permeabilized by using the cytofix/perm and
perm/wash solutions (eBioscience) according to the manufactur-
er’s instructions. Then, the appropriate antibody mixes or single
stains diluted in permeabilization solution in the recommended
concentrations were added for 30 minute incubation on ice under
dark conditions. Cells were then washed and transferred to FACS
acquisition tubes for analysis in FACScalibur instrument and
CellQuest software.
Cell sorting of pulmonary lymphocyte subpopulations
Pulmonary single cell suspensions from at least 7 individual
C57BL/6 animals were pooled together and underwent Red Cell
Lysis (Sigma-Aldrich, Israel) according to manufacturer’s instruc-
tions. Lymphocytes were enriched by incubation in complete
medium (described above) in sterile tissue culture 10 cm plates
(Falcon, USA) for overnight in 37 degrees Celsius to allow
adherence of cells. Non-adherent cells were gently collected,
washed and passed through a cell strainer. The cells were
extracellularly stained with FITC-anti DX5 and PE-Cy5.5-anti
CD3. Staining was performed as described above with the
exception that RPMI-1640 medium with 0.5% FCS was used
and not standard FACS buffer. Cells were transferred into sorting
tubes in a concentration of 1610
7 cells/ml diluted in RPMI. Cells
were sorted using FACSvantage instrument into NK cells and T
cells by applying gates on appropriate physical (Forward and Side
Scatters typical for lymphocytes) and fluorescent characteristics.
NK cells were defined as DX5
+CD3
2 cells and T cells were
defined as DX5
2CD3
+ cells within the lymphocytes’ gate. In each
sorting session, 5610
5–1610
6 cells of each desired subpopulation
were collected. The acquisition and collection tubes were kept in
ice throughout the entire process. The purity of each sorted
subpopulation was .95% as validated by post-sorting staining
with PE-anti Thy1.2 and APC-anti NK1.1. Cells were sorted from
naı ¨ve animals, as well as from certain time points after infection
with 0.16LD50.
ELISA
Quantification of murine TNFa, IL-6, IFNc and IL-17A was
performed by using Duo-Set ELISA kits (R&D Systems) according
to manufacturer’s instructions. The kit for IL-17A is specific to this
isoform and does not cross react with other isoforms.
Real time PCR
Total RNA was purified by using RNAeasy kit (Qiagen,
Germany) and converted to cDNA using OmniScript reverse
transcriptase (Qiagen, Germany) according to manufacturer’s
instructions. For real-time PCR, 100 ng cDNA was amplified in
50 ml reaction using 500 nM primers, 5 mM Magnesium, 0.2 mM
dNTP, PCR buffer, 100 nM Super ROX, AmpliTaq Gold DNA
polymerase and EVA Green. Specific primers allowed quantifica-
tion of the cytokines IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-
10, IL-12p40, IL-13, IL-15, IL-17A, IL-18, IFNc, TNFa, TGFb,
MIC-1 and GM-CSF. The sequences of the primers were
published previously [48]. Experiments were done in triplicates
and analyzed using the 7500 ABI Real Time PCR System
(Applied Biosystems, USA). Analysis was performed as followed:
for each cell sample the Ct value of GAPDH (the normalizing
house keep gene used) was subtracted from the Ct value of each
specific cytokine to obtain the DCt value (Ctcytokine-
CtGAPDH=DCt). The DCt values in cells derived from naı ¨ve mice
were used as reference values to get the DDCt value (DCtxinfected-
IL-17A in Lung LVS Infection
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2DDCt ratio (fold of change, relative to
naı ¨ve cells).
Supporting Information
Figure S1 (A) CD69 expression analysis on gated NK cells
(NK1.1+CD3-TCRab- cells) in the lungs (closed diamonds) and
MdLN (open squares) at the indicated time points after infection
(B) CD69 expression analysis on gated T cells (NK1.1-
CD3+TCRab+ cells). (C) and (D) show the total numbers of NK
or T cells, as defined above; Cells were pooled from three animals
at each time point and analyzed; Figure shows a representative
experiment out of three independent experiments performed.
Each time point included three animals.
Found at: doi:10.1371/journal.pone.0011176.s001 (1.40 MB EPS)
Figure S2 (A) CD69 expression analysis on gated NK cells
(NK1.1+CD3-TCRab- cells) in the lungs (closed diamonds) and
MdLN (open squares) at the indicated time points after infection
(B) CD69 expression analysis on gated T cells (NK1.1-
CD3+TCRab+ cells). (C) and (D) show the total numbers of NK
or T cells, as defined above; Cells were pooled from three animals
at each time point and analyzed; Figure shows a representative
experiment out of three independent experiments performed.
Each time point included three animals.
Found at: doi:10.1371/journal.pone.0011176.s002 (1.59 MB EPS)
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